Clinical trial
Multicenter, Open-label, Exploratory Phase I Pilot Study to Investigate Safety, Pharmacodynamics, and Pharmacokinetics of Immunological Effects and Activity of Combining Multiple Doses of IMAB362 With Immunomodulation (Zoledronic Acid, Interleukin-2) in Patients With Advanced Adenocarcinoma of the Stomach, the Lower Esophagus, or the Gastroesophageal Junction
NCT01671774 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Open-label, Exploratory Phase I Pilot Study to Investigate Safety, Pharmacodynamics, and Pharmacokinetics of Immunological Effects and Activity of Combining Multiple Doses of IMAB362 With Immunomodulation (Zoledronic Acid, Interleukin-2) in Patients With Advanced Adenocarcinoma of the Stomach, the Lower Esophagus, or the Gastroesophageal Junction
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 16, 2012
- Completion date
- October 13, 2014
- Enrollment
- 29 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
cldn18.2-positive adenocarcinoma of esophagus, cldn18.2-positive adenocarcinoma of the gastroesophageal junction, cldn18.2-positive gastric adenocarcinoma